Launching novel oncology therapies in Asia: Identifying and communicating value
Novel cancer therapies are offering patients new treatments and better outcomes worldwide. Recent changes in healthcare policies across APAC have reignited interest in the region as a strong market for oncology, such as China's fast tracking approval of therapies for severe and rare diseases and Vietnam's plan to cover health insurance for 80% of the population. Unfortunately, the often eye-watering costs of these new therapies means that, currently, for the many patients who still have to pay for treatment out of pocket, novel therapies are beyong reach. Pharma brands need to demonstate clear value if they want to achieve success.
Communication trends in Latin America: How pharma can utilise new and emerging digital platforms
Smartphones and digital technology have revolutionised the way we communicate with one another. Latin America, like other parts of the world, has been swift to embrace new and emerging digital applications, in particular WhatsApp, which has become an ubiquitous tool for people in both their personal lives and in business. As digital communication channels increase in popularity, it is important for the pharmaceutical industry to keep in step. Understanding how to leverage platforms like WhatsApp as both a means of generating customer insight and as a stakeholder engagement tool, will help pharma companies to have impact in this exciting and ever-changing region.
Market access in Brazil: All eyes on Spinraza
Director Rachel Howard asks, “What does Brazil’s unprecedented risk-sharing agreement in Spinal Muscular Atrophy (SMA) mean for the future of market access in Brazil?
In April 2019, Brazilian Health Minister Luiz Henrique Mandetta announced a pilot agreement for access to Biogen’s Spinal Muscular Atrophy (SMA) treatment Spinraza (nusinersen) through the Sistema Único de Saúde (SUS). This is the first agreement in Brazil to include a risk-sharing model, in which the government only pays for the drug if there is improvement in the patient's health. In a country where it typically takes years for innovative pharmaceutical products to be reimbursed in the public sector, manufacturers wishing to obtain market access for their products in Brazil will be watching this example closely to see how it plays out.
Real world evidence research breakfast seminar
We were delighted to attend and present a paper at the Tech Observer event in Singapore earlier this month
APAC Director Pei Li Teh, and Research Manager, Colin Tan, attended the event. Pei Li presented the paper ‘Inhale, exhale: How using real world data helped asthma patients breathe easier across Asia’. In her paper she demonstrated how published real world data research provided pharma companies with an in-depth understanding of asthma patients’ across Asia. The data provided the healthcare community with a tool to supply tailored communications supporting different patient types, instead of a ‘one size fits all’ approach.
Research Partnership welcomes Jeanne Penn
We are delighted to announce that Jeanne Penn has joined the Singapore office as a Senior Research Executive.
Jeanne previously worked at Cello Health Insight in New York City on the qualitative team, where she was involved in all parts of the research process, from writing proposals to delivering reports. She’s worked in various therapy areas, and has a particular interest in rare diseases and mental health. In a prior role, she co-led the first Diversity & Inclusion initiative and was awarded the Young Professionals Grant to attend the Qualitative Research Consultants Association (QRCA) conference. Jeanne graduated from Hamilton College, and interned at Hall & Partners where she was first introduced to healthcare market research.